Phase 2 N=452 A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
Asthma
Primary: Annual Asthma Exacerbation Rate (AER) — 0.90; 0.91; 0.97 AER events/person-year — p=0.709
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease
Sanfilippo Syndrome
Primary: Number of Participants With Overall Response Using Bayley Scales of Infant Development Assessment Third Edition (BSID-III) — 0; 2; 1 participants — p=0.4615
Phase 2 N=14 Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Response Rates After Amrubicin + Lenalidomide + Dexamethasone, Per International Myeloma Working Group Uniform Response Criteria — 0; 7.6; 7.6; 15.4 percentage of…
Phase 2 N=346 A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
Melanoma · Metastatic Melanoma · Skin Cancer
Primary: Progression-Free Survival (PFS): Time to Event — 54; 56; 53; 60 days — p==0.071
Phase 2 N=12 A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
Opioid Abuse · Opioid Dependence
Primary: Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS) — 12.6; 1.3 units on a scale
Phase 2 N=8 Prospective Trial Comparing Response to Hyperbaric Oxygen Treatment in Patients With Interstitial Cystitis
Interstitial Cystitis
Primary: Global Response Assessment (GRA) — 0; 1; 1; 0 number of participants
Phase 2 N=12 Buprenorphine's Dose Response Curve
Opioid-related Disorders
Primary: Peak Change From Baseline in Drug Effect Assessed by Visual Analog Scale (VAS) — 17.75; 27.25; 29.63; 58.25 units on a scale
Phase 2 N=195 Treatment of Hypochondriasis With CBT and/or SSRI
Hypochondriasis
Primary: 25% Improvement on Both Whiteley Index and H-YBOCS-M — 21; 13; 20; 25 Participants
Phase 2 N=26 Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
HIV I Infection
Primary: Part A: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 6; 6; 1; 6 participants
Phase 2 N=44 Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Adjusted Mean Percent Change From Baseline in Insulin Sensitivity at Week 12 (Last Observation Carried Forward [LOCF]) — -9.99; 7.98 % Change of Baseline Insulin…
Phase 2 N=171 A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: The Primary Efficacy Endpoint of This Study is the Weekly Average Daily NPRS (Average Pain) — 5.3; 4.9 units on a scale
Phase 2 N=461 Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old
Infections, Meningococcal
Primary: Number of Subjects With an Immune Response to Different Meningococcal Serogroups — 30; 32; 26; 27 Participants
Phase 2 N=10 Decitabine for High-Risk Sickle Cell Disease
Neutropenia · Sickle Cell Disease
Primary: The Percentage Change in HbF Level From Baseline to the Average Over the Final 1 Month of Study. — 1; 1; 6 Participants
Phase 2 N=378 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
Brain Tumor · Central Nervous System Tumor
Primary: Event-free Survival — 0.614; 0.685; 0.372 Probability of EFS at 5 years
Phase 2 N=68 Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After End of Study Drug Treatment (SVR12) — 86.4; 100 Percentage of Participants